ArticleInternational journal of cancer2025
Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Personal history of cancer is an independent risk factor for developing lung cancer. However, it is not considered in the current US lung cancer screening (LCS) guidelines. In this study, we assessed the risk of developing lung cancer among cancer survivors across 24 different sites of first primary cancer stratified by their LCS eligibility status. Using data from the Patient History Database at the University of Texas MD Anderson Cancer Center, we calculated and compared the cumulative incidence of second primary lung cancer, the overall and the LCS eligibility status-specific, stratified by the site of first primary cancer among cancer survivors. We found that among lung, head and neck (H&N), bladder, cervical, breast, and prostate cancer survivors, the risks of second primary lung cancer were statistically significantly higher compared to the overall risk among all cancer survivors (i.e., all cancer sites combined). Risk ratios (RR) ranged between 1.14 (95%CI:1.00-1.28, p = 0.0431) among prostate cancer survivors to 2.9 (95%CI:2.58-3.26, p < 0.001) among H&N cancer survivors. Other than first primary lung cancer (RR: 1.33; 95%CI:1.14-1.57; p < 0.001), H&N (RR: 1.73; 95%CI:1.45-2.05; p < 0.001) and bladder (RR: 1.32; 95%CI:1-1.74; p = 0.0483) cancer survivors, who were non-eligible for LCS, had significantly higher lung cancer risk than all cancer survivors. In conclusion, H&N, bladder, cervical, breast, and prostate cancer survivors have a high risk of developing second primary lung cancer. Specifically, personal history of H&N and bladder cancer, even among non-eligible for LCS individuals, remain at a sufficiently high risk, which warrants further consideration as an independent eligibility factor for LCS guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.